Reporter brief
Treatment of Choroidal Subretinal Neovascularization With Agents Directed Against the Immune Response
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report the study outcomes, so whether any treatment prevented neovascularization or improved vision cannot be determined from this text
- The sample size and participant completion rates are not reported, limiting assessment of statistical power and internal validity
- No effect sizes or statistical significance values are provided for any treatment comparison
Study design and sample
Rct; Human.
Participants 55 years of age and older with age-related macular degeneration (AMD) and drusen larger than 63 μm. Vision in the study eye was between 20/20 and 20/400.
- Design
- Rct
- Sample
- —
- Journal
- National Eye Institute (NEI)
- Published
- Nov 29, 2016
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.